|
|
DRUG INTERACTIONS
LIPOSYN III drug label information in our database does not contain a dedicated section on drug interactions. Please check subsections of WARNINGS AND PRECAUTIONS as well as other sources.
|
OVERDOSAGE
In the event of fat overload during therapy, stop the infusion of Liposyn III until visual inspection of the plasma, determination of triglyceride concentrations, or measurement of plasma light-scattering activity by nephelometry indicates the lipid has cleared. Re-evaluate the patient and institute appropriate corrective measures. See WARNINGS and PRECAUTIONS.
|
CONTRAINDICATIONS
LIPOSYN III 30% PHARMACY BULK PACKAGE IS NOT INTENDED FOR DIRECT INTRAVENOUS ADMINISTRATION. DILUTING LIPOSYN III 30% TO A 10% OR 20% CONCENTRATION WITH AN INTRAVENOUS FLUID SUCH AS NORMAL SALINE OR OTHER DILUENT DOES NOT PRODUCE A DILUTION THAT IS EQUIVALENT IN COMPOSITION TO LIPOSYN III 10% OR 20% I.V. FAT EMULSIONS, AND SUCH A DILUTION SHOULD NOT BE GIVEN BY DIRECT INTRAVENOUS ADMINISTRATION (e.g., THROUGH A Y-CONNECTOR).
The administration of Liposyn III (intravenous fat emulsion) is contraindicated in patients demonstrating disturbances in normal fat metabolism such as pathologic hyperlipemia, lipoid nephrosis or acute pancreatitis if accompanied by hyperlipemia.
Partly used containers must not be stored for later use. Do not use any bottle in which there appears to be an oiling out of the emulsion.
|
References
-
Levene M, Wigglesworth J, Desai R. Pulmonary fat accumulation after Intralipid infusion in the preterm infant.
Lancet II: 815-818, (Oct. 18), 1980.
-
Dahms B, Halpin T. Pulmonary arterial lipid deposit in newborn infants receiving intravenous lipid infusion.
J. Pediatrics: 97:800-805, (Nov.), 1980.
-
American Academy of Pediatrics: Use of intravenous fat emulsion in pediatric patients.
Pediatrics 1981; 68:5 (Nov.):738-43.
Revised: August, 2005
| | |
|
©Hospira 2005
|
EN-1012
|
Printed in USA
|
HOSPIRA, INC., LAKE FOREST, IL 60045 USA
|
|
|
|
-- advertisement --
|
